

# Clinical trials of evacetrapib

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 cardiovascular prevention

| Trial   | Treatments  | Patients   | Trials design and methods                       |
|---|---|--|---|
| <b>evacetrapib vs placebo</b>   |   |  |   |
| <a href="#">ACCELERATE , 2017</a><br>[NCT01687998]<br>n=6038/6054<br>follow-up: | evacetrapib at adose of 130 mg<br>versus<br>placebo | Patients at a High-Risk for Vascular<br>Outcomes who had at least one of the<br>following conditions: an acute coronary<br>syndrome within the previous 30 to 365<br>days, cerebrovascular<br>atherosclerotic disease, peripheral vascular<br>arterial disease, or diabetes mellitus with<br>coronary artery disease | Parallel groups<br>double-blind<br>37 countries |

More details and results :

- CEPT inhibition for cardiovascular prevention in all type of patients at <http://www.trialresultscenter.org/go-Q340>
- HDL increasing drugs for cardiovascular prevention in all type of patients at <http://www.trialresultscenter.org/go-Q503>

## References

### **ACCELERATE, 2017:**

Lincoff AM, Nicholls SJ, Riesmeyer JS, Barter PJ, Brewer HB, Fox KAA, Gibson CM, Granger C, Menon V, Montalescot G, Rader D, Tall AR, McErlean E, Wolski K, Ruotolo G, Vangerow B, Weerakkody G, Goodman SG, Conde D, McGuire DK, Nicolau JC, Leiva-Pons JL, Pe Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. N Engl J Med 2017;376:1933-1942 [[28514624](#)]